MX2018013973A - Metodos de tratamiento de sindromes de comportamiento usando pipradrol. - Google Patents

Metodos de tratamiento de sindromes de comportamiento usando pipradrol.

Info

Publication number
MX2018013973A
MX2018013973A MX2018013973A MX2018013973A MX2018013973A MX 2018013973 A MX2018013973 A MX 2018013973A MX 2018013973 A MX2018013973 A MX 2018013973A MX 2018013973 A MX2018013973 A MX 2018013973A MX 2018013973 A MX2018013973 A MX 2018013973A
Authority
MX
Mexico
Prior art keywords
methods
pipradrol
treating behavioral
behavioral syndromes
syndromes
Prior art date
Application number
MX2018013973A
Other languages
English (en)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2018013973A publication Critical patent/MX2018013973A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporcionan métodos para tratar síndromes de comportamiento mediante la administración de una composición farmacéutica de pipradrol o una sal farmacéuticamente aceptable del mismo. Los métodos pueden usarse para tratar el Trastorno de Déficit de Atención (TDA) y el Trastorno de Déficit de Atención e hiperactividad (TDAH).
MX2018013973A 2016-05-26 2017-05-25 Metodos de tratamiento de sindromes de comportamiento usando pipradrol. MX2018013973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662341855P 2016-05-26 2016-05-26
PCT/US2017/034443 WO2017205606A1 (en) 2016-05-26 2017-05-25 Methods of treating behavioral syndromes using pipradrol

Publications (1)

Publication Number Publication Date
MX2018013973A true MX2018013973A (es) 2019-03-28

Family

ID=60408578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013973A MX2018013973A (es) 2016-05-26 2017-05-25 Metodos de tratamiento de sindromes de comportamiento usando pipradrol.

Country Status (10)

Country Link
US (3) US9827233B1 (es)
EP (1) EP3439657A4 (es)
JP (1) JP2019517469A (es)
KR (1) KR20190013737A (es)
CN (1) CN109414435A (es)
AU (1) AU2017268795A1 (es)
CA (1) CA3025473A1 (es)
IL (1) IL262986A (es)
MX (1) MX2018013973A (es)
WO (1) WO2017205606A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9351968B1 (en) * 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
EP3439657A4 (en) * 2016-05-26 2019-12-18 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISTURBANCES USING PIPRADROL
KR20200053570A (ko) * 2017-09-12 2020-05-18 오비드 테라퓨틱스 인크. 기면증의 치료에서 가복사돌의 사용
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
GB201911056D0 (en) * 2019-08-02 2019-09-18 Sanchez Hector Mario Treatment of ADD/ADHD
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc A canceled gaboxadol ring and its use for the treatment of psychiatric disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US5650521A (en) * 1995-12-29 1997-07-22 Guilford Pharmaceuticals Inc. Pyrrolidine derivatives
AU2007346591A1 (en) * 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US8865746B2 (en) 2008-07-18 2014-10-21 Zafgen, Inc. Methods of treating an overweight or obese subject
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20100260844A1 (en) * 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2011020030A2 (en) * 2009-08-13 2011-02-17 The General Hospital Corporation Methods and compositions to prevent addiction
ES2595251T3 (es) 2010-05-25 2016-12-28 Inserm - Institut National De La Santé Et De La Recherche Médicale Métodos y composición farmacéutica para el tratamiento de un trastorno alimentario con inicio temprano en un paciente
PT3272342T (pt) * 2011-03-23 2021-07-12 Ironshore Pharmaceuticals & Dev Inc Processos e composições para o tratamento de síndrome de défice de atenção
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
EP3439657A4 (en) * 2016-05-26 2019-12-18 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISTURBANCES USING PIPRADROL

Also Published As

Publication number Publication date
CA3025473A1 (en) 2017-11-30
US20170340619A1 (en) 2017-11-30
WO2017205606A1 (en) 2017-11-30
CN109414435A (zh) 2019-03-01
US9827233B1 (en) 2017-11-28
US10493069B2 (en) 2019-12-03
US20190076415A1 (en) 2019-03-14
AU2017268795A1 (en) 2018-11-22
JP2019517469A (ja) 2019-06-24
KR20190013737A (ko) 2019-02-11
US20180036298A1 (en) 2018-02-08
EP3439657A1 (en) 2019-02-13
EP3439657A4 (en) 2019-12-18
IL262986A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
MX2018013973A (es) Metodos de tratamiento de sindromes de comportamiento usando pipradrol.
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
NZ761388A (en) Methods of treatment for cystic fibrosis
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2021007651A (es) Inhibidores de ezh2 para tratar linfomas.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2015009276A (es) Donadores de nitroxilo con indice terapeutico mejorado.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
NZ725354A (en) Transdermal formulations of pergolide and uses thereof
MX2019008000A (es) Metodo de administracion de compuestos donadores de nitroxilo.
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
AR107027A1 (es) Moduladores de actividad complementaria